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The in¯uence of nitric oxide on in vivo human skeletal
muscle properties
J . P . F O L L A N D , H . M A A S and D . A . J O N E S
School of Sport and Exercise Sciences, University of Birmingham, Birmingham, UK
ABSTRACT
We have investigated the action of exogenous nitric oxide (NO) on the strength and contractile
properties of human skeletal muscle working in vivo. Maximum isometric voluntary contraction force
(MVC) of the quadriceps was measured and superimposed electrical stimulation was used to
estimate the level of activation and `true maximum force' (TMF). Force±frequency relationships were
determined to assess changes in contractile properties of the muscle. Subjects in the experimental
group (E, n  10) were measured before and during two separate periods of treatment with different
doses of glyceryl trinitrate, a NO donor, delivering 100 (GTN100) or 200 (GTN200) lg h±1 as a trans-
dermal patch. A control group (C, n  6) was measured during two similar periods whilst taking an
oral placebo. There was a signi®cant increase in strength with GTN200 (MVC: +5.15%; TMF:
+3.87%). There was no change in the strength of group C. There was a trend towards reduced forces
at submaximal frequencies with GTN administration but the most notable change was a decline in
twitch force (approximately 12%, P < 0.05) with GTN100 treatment and this remained depressed
throughout the study. No changes were seen in the contractile properties of the control group C. The
present results show that GTN treatment increased maximum voluntary strength but decreased
twitch tension. The time course and dose±response characteristics indicate that these are two
separate actions of NO on human muscle working in vivo.
Keywords force±frequency relationship, glyceryl trinitrate (GTN), maximum voluntary contraction
(MVC), nitric oxide (NO), skeletal muscle.
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The largest determinant of muscle strength is its size,
speci®cally the physiological cross-sectional area (CSA),
which accounts for about 50% of the variation in
isometric strength between individuals (Chapman et al.
1984). The remainder of the inter-subject variation has
been variously ascribed to morphological and neurol-
ogical factors such as differences in ®bre type compo-
sition, angle of ®bre pennation or the level of motor
unit activation (see Jones et al. 1989).
The size of a muscle changes relatively slowly but
short-term ¯uctuations in strength have been
observed. Gauthier et al. (1996, 1997) found a signi®-
cant circadian rhythm of elbow ¯exor strength with an
amplitude of 7±8%, which was attributed to variations
in central nervous system command and the contract-
ile state of the muscle. Other studies have measured
changes during the menstrual cycle and the effect of
female reproductive hormones on muscle function
with equivocal results. Some investigators have found
that the reproductive hormones have no in¯uence on
muscle function (Greeves et al. 1997, Gur 1997) but
there are other well-documented reports of ¯uctua-
tions (~10%) in maximum voluntary force during the
menstrual cycle (Phillips et al. 1996, Sarwar et al. 1996).
These changes appear too rapid for the synthesis of
contractile protein or other morphological changes
and suggest that sex hormones may have some ino-
tropic effect resulting in short-term ¯uctuations in
strength.
Since its discovery as a physiologically active
substance, nitric oxide (NO) has been found to play a
key role in many bioregulatory systems in addition to
the control of vascular tone (e.g. Moncada et al. 1991,
Moncada & Higgs 1993). Nitric oxide has been found
to mediate some of the vasodilatory effects of
oestrogen on smooth muscle (Darkow et al. 1997,
Huang et al. 1998) and there is evidence that oestrogen
increases the expression of calcium-dependent nitric
oxide synthase (NOS) in skeletal muscle (Weiner et al.
1994).
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The neuronal isoform of nitric oxide synthase
(ncNOS) has been found in skeletal muscle cells
localized to the sarcolemma (Kobzik et al. 1994,
Grozdanovic et al. 1996). Other investigators have
found ncNOS closely associated with mitochondria
(Kobzik et al. 1995, Wakayama et al. 1997) and
concentrated around the neuromuscular junction
(Kusner & Kaminski 1996, Grozdanovic & Gossrau
1998). Endothelial NOS (ecNOS) appears to be
distributed throughout the sarcoplasm of some ®bres,
irrespective of the ®bre type.
There are con¯icting reports of the action of NO
on the strength and contractile properties of skeletal
muscle. There have been recent reports of an increase
in maximum isometric force (Reid et al. 1996), of no
effect (Marechal & Beckers-Bleukx 1996, Albertini
et al. 1997, Chen et al. 1998) or a decrease (Perkins
et al. 1997, Galler et al. 1997). Morrison et al. (1996)
found no change in isometric force but did ®nd an
increase in isokinetic force and power. Murrant &
Barclay (1995) found an increase in the sustained force
of intermittent tetani (50 Hz) with an in vitro prepara-
tion, although this was only signi®cant at the slowest
repetition rate.
In addition to any effect on maximum force,
endogenous NO may modulate excitation±contraction
coupling. Kobzik et al. (1994) found that the adminis-
tration of a NOS inhibitor caused a left shift of the
force±frequency curve and argued that NO may,
therefore, inhibit (right shift) the force±frequency
relationship. Such an action of NO is supported by the
®ndings of Perkins et al. (1997) although Reid et al.
(1996) found a left shift with increased forces at low
frequencies of stimulation in response to NO donation.
To date, the role of NO in skeletal muscle has been
investigated largely in vitro or in animal preparations.
The purpose of the present study is to determine
whether treatment with a NO donor could affect
maximum isometric force and the contractile properties
of human skeletal muscle in vivo. For this purpose,
glyceryl trinitrate (GTN) was employed as it is a well-
known organic NO donor that has been used for many




Eighteen volunteers, ®ve female and 13 male, were
recruited from amongst staff and students at the
University of Birmingham. Four of the female subjects
were oral contraceptive pill users. All subjects were
active recreationally and nine had been involved in
systematic strength training for over 6 months.
Subjects were randomly assigned to either an experi-
mental group (E) or a control group (C). Two male
subjects withdrew from the study. Details of the
subjects who completed the study are given in Table 1.
The subjects gave their informed consent,
completed the standard health questionnaire and were
screened for contra-indications to glyceryl trinitrate
(GTN) (e.g. low blood pressure, migraine, etc.) before
the start of the study. The study was approved by the
local Ethics Committee.
Experimental protocol
Measurements of maximum quadriceps isometric force
and the force±frequency relationship were made on
both legs. Each subject was measured at the same time
of day throughout the study and the measurements
from both legs were averaged for each testing occasion.
At the end of the study, subjects were given a ques-
tionnaire to rate the consistency of their lifestyle, level
of motivation, perception of their strength and any
side-effects.
Glyceryl trinitrate was administered via a trans-
dermal patch (Nitro-Dur, Schering-Plough, Ireland)
placed on the lateral aspect of the shoulder for 5 h and
removed 1 h prior to the strength measurements. The
patches released 100 or 200 lg h±1 into the blood-
stream, so that a total of 500 lg (100GTN) or 1000 lg
(200GTN) of GTN was delivered over 5 h.
The side-effects of GTN administration are mild
headache and light-headedness, but, consequently, a
strict double blind design was not applicable. Subjects in
group E were measured on nine occasions over a 3-week
period. A diagram of the experimental protocol is shown
in Fig. 1. The ®rst three measurements were designated
as baseline (B1). The next two measurements were taken
on consecutive days after 100 lg h±1 of GTN
(100GTN) had been administered. Two more measure-
ments were taken during a washout period (second
baseline, B2) and ®nally, on two consecutive days at the
end of the third week, two measurements were made
after administration of 200 lg h±1 of GTN (200GTN).
Five subjects in group E (designated E5) were
assessed on four occasions over an additional 2-week
period. A placebo (P) consisting of 0.5 g glucose in a
single gelatine capsule, taken 6 h prior to measurement








Experimental 8 2 23  3 176  7 75  8
Control 3 3 25  2 174  8 74  18
Values are mean  SD.
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was administered before the ®rst two of these addi-
tional measurements. The third and fourth additional
measurements were made with the subjects receiving
200 lg h±1 GTN (200GTN#2).
Although there were no placebo patches, subjects in
the experimental group E were told that there was a
50% chance of receiving a placebo patch during the 100
and 200GTN periods and subjects in groups E5 and C
were told that the placebo capsule was another form of
NO donor.
The control group (C) was measured three times a
week (Monday, Wednesday and Friday) for 4 weeks.
During the third and fourth weeks, these subjects took
two separate batches of oral supplements everyday.
Both batches of supplements were placebo (5 g day±1
glucose in gelatin capsules). Each of the four weeks
were treated as an independent testing period desig-
nated as baseline 1 (B1), baseline 2 (B2), placebo 1 (P1)
and placebo 2 (P2), respectively.
Materials
Quadriceps strength was measured using a calibrated
U-shaped aluminium strain gauge (Jones & Parker
1989) with a linear response up to 1000 N. The strain
gauge was interfaced with a computer via an ampli®er
so the subjects received direct visual feedback.
For electrical stimulation of the quadriceps two
large aluminium electrodes (~100 cm2) covered in a
damp paper were applied proximally and distally to the
anterior surface of the thigh. A CED-1401 (Cambridge
Electronic Design, England) triggered the electrical
stimuli (pulse width 50 ls, up to 200 V, Digitimer
DS7, England). The strength of the stimulus was
manipulated by changing the current, within a range of
190±380 mA for force±frequency testing and 280±
500 mA at 1.25 Hz for twitch superimposition during
the MVC.
Strength testing
The maximum isometric voluntary strength of each
quadriceps was measured in a conventional strength-
testing chair (Parker et al. 1990) at 1.57 rads (90°) of
¯exion. Subjects performed four voluntary maximal
knee extensions of at least 2-s duration separated by a
minimum of 30 s rest. Subjects received loud verbal
encouragement throughout all maximum efforts. The
mean of the highest values from each leg was taken as
the force of MVC.
A percutaneous twitch superimposition technique
(Rutherford et al. 1986) was used on the third and
fourth maximum contractions of each leg with the
subjects in group E. The quadriceps were stimulated
just before and during each maximum contraction with
a train of single twitches at 1.25 Hz with a current
suf®cient to generate a twitch force of ~10% of MVC.
The magnitude of twitches before and superimposed
during a maximum contraction were compared to
estimate the level of activation and `true maximum
force' (TMF). The mean of two twitches was used to
measure resting and superimposed twitches.
Force±frequency relationship
A comparison of the forces generated by a range of
electrical stimulation frequencies (1, 10, 20, 50, 80 and
100 Hz) was used as an indication of changes in E±C
coupling and/or speed of the muscle. Stimulation was
with ®ve single twitches at 1 Hz and for 2 s at the other
frequencies with 20 s rest between each tetanus. The
response to 10 and 20 Hz stimulation had the greatest
variability and so these frequencies were measured
twice. Maximum tetanic-stimulated force was 25±35%
of MVC. The forces were always recorded in the same
order to ensure that any effects of fatigue or post-
tetanic potentiation remained constant.
Statistics
A repeated measures ANOVA was used to analyse the
changes within groups. The Bonferroni post hoc test
was used to identify signi®cant differences between
conditions (group E) or periods (group C). A probab-
ility level of <0.05 was accepted as the minimum value
for statistically signi®cant differences.
RESULTS
Most of the subjects experienced a mild headache and
light-headedness with the administration of GTN200
that resolved in the hour between removing the patch
and testing muscle function. However, two male
subjects experienced a more severe headache with
(a)
(b)
Figure 1 The experimental protocol for group E. Measurement days
are denoted by bold. (a) The measurements for all of group E
(n  10). (b) The additional measurements for half of group E
(n  5).
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GTN100 and withdrew from the rest of the study. The
subjects reported a consistent and maximal level of
motivation, a consistent lifestyle and no change in their
perceived strength. Mean absolute values for MVC,
level of activation and TMF for group E during each
condition are shown in Table 2(a). The corresponding
values of the four periods of MVC measurement for
group C are shown in Table 2(b). There were no
interactions between the observed effects of GTN
treatment and training status, strength or gender.
Maximum voluntary strength
During the GTN200 period, the MVC of group E
increased by 5.15  1.24% (Mean  SEM, range ±1.4
to 12.0%) compared with B1. There was no signi®cant
change in MVC between GTN100 and B1 (0.05 
0.53%, range ±2.4 to 2.5%). For the ®ve subjects who
completed the additional phase of investigation (E5),
there were no signi®cant differences in MVC between
the ®rst treatment period with GTN200, the placebo (P)
or the second GTN200#2 (Fig. 2).
For the control group C, there were no signi®cant
differences in MVC between any of the four periods,
although in B2, P1 and P2 the MVC was, on average,
lower than in B1 (Table 2). The greatest individual
changes in this group ranged from ±5.0 to 3.4%.
Level of voluntary activation and true maximum force
Figure 2 shows the mean individual changes in MVC
and the level of activation relative to B1 during the
treatment periods for group E and for the additional
measurements on group E5. The estimated level of
activation of group E did not change signi®cantly
during any condition (Table 2). The average level of
voluntary activation for all of group E overall condi-
tions was 96.8  0.6% (mean  SEM). Correcting the
MVC for the level of activation showed that during
GTN200 the TMF was signi®cantly higher than during
B1 and B2 (Table 2), although the magnitude of this
increase was slightly smaller than for the MVC
(compare Figs 2 and 3). Overall, the trend of MVC and
TMF changes was very similar across all the conditions.
There were no differences between TMF measured
during GTN100 and B1.
Force±frequency relationship
The results are expressed as the change in force relative
to 100 Hz force (Fig. 4). There was a trend towards a
decline in relative force at all the submaximal
frequencies for subjects in group E but the fall in
relative submaximal forces was especially noticeable at
1-Hz stimulation.
B1 GTN100 B2 GTN200
(a)
MVC (N) 678  34 679  35 693  35 712  37*
TMF (N) 704  38 709  40 712  38 731  40*
Activation (%) 96.4  1.2 95.9  1.5 97.4  1.1 97.5  0.8
B1 B2 P1 P2
(b)
MVC (N) 565  76 561  79 561  69 559  77
*Signi®cantly higher (P < 0.05) than B1 and B2.
Table 2 (a) Mean MVC, estimated
true maximum force (TMF) and level
of activation during each condition for
group E (mean  SEM, n = 10). (b)
Mean MVC for group C during each
period (mean  SEM, n = 6)
Figure 2 Mean change in MVC and the level of activation compared
with B1. Every measurement is shown, for all of group E (n  10,





Figure 3 Mean change in true maximum force (TMF) for group E
relative to B1 (mean  SEM, n  10).
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In group E, signi®cant differences were found at 1,
20 and 80 Hz (repeated measures ANOVA, P < 0.05).
Speci®cally for 1 Hz, during B2 and GTN100
compared with B1 and at 80 Hz between B1 and
GTN200 (post hoc Bonferroni test, P < 0.05). In
group C, no signi®cant differences were found between
any of the four periods for any frequency. The absolute
force generated by 100-Hz stimulation remained very
consistent for both groups (data not shown).
DISCUSSION
The results presented here indicate that NO adminis-
tration can modulate skeletal muscle function in vivo.
The MVC showed a progressive increase of about 5%
over a number of days that was signi®cant with
GTN200 administration and persisted for at least
7 days. There was a consistent trend towards lower
relative forces at submaximal frequencies of electrical
stimulation with both doses of GTN and this was most
pronounced with the reduced twitch force (about 12%)
that was sustained for several days.
There are two features of the increase in strength
that require some comment. The ®rst is the small size
of the change which raises the question as to whether it
represents a `real' increase in strength. The second
feature is the time course of change that was much
slower than had been anticipated.
There are a number of reasons to think that the
small increase in strength was not owing to increased
muscle activation or experimental bias. An increase in
activation, through improved central drive or
co-ordination, could facilitate an increase in MVC, but
while there continues to be some debate (Hales &
Gandevia 1988), many studies have demonstrated that
healthy untrained subjects can maximally activate their
quadriceps muscle (Belanger & McComas 1981, Ruth-
erford et al. 1986). In our present work, the interpolated
twitches veri®ed that our subjects were consistently
well motivated, with high and stable levels of activation
and even after making allowance for any ¯uctuations in
activation, the TMF increased signi®cantly (»+4%)
after treatment with GTN200. The observation that
strength did not increase with the lower dose of GTN
(GTN100) suggests that experimental bias was not
in¯uencing the results. The design of the trial and side-
effects of GTN meant that both subjects and investi-
gators were aware of the treatment, yet this did not
appear to in¯uence the motivation or effort put into the
contraction by the subjects. The consistent MVC of the
control group over the 4 weeks also indicates that there
were no signi®cant learning effects or other artefacts
in¯uencing the results.
MVC changes of the magnitude we have observed
are similar to strength changes reported as a result of
the circadian rhythm (Gauthier et al. 1996, 1997) or the
menstrual cycle (Phillips et al. 1996, Sarwar et al. 1996).
We avoided any diurnal effects by taking measurements
at the same time of day for each subject. Group E
contained only two females, one was taking the oral
contraceptive pill and both showed changes that were
typical of their male colleagues for all of the measures
examined.
The evidence we have accumulated strongly suggests
that the increases in strength with GTN were not owing
to increases in muscle activation or to experimental bias
and, therefore, represents a true improvement in
contractile function.
The increased strength following GTN administra-
tion persisted for several days, which suggests a lasting
modi®cation of function. The lack of effect during the
100-GTN period may have been a consequence of the
low dose but the data in Fig. 2 also suggest a slow onset
of the effect as strength continued to rise during the
baseline period B2. The prolonged nature of this effect
is emphasized by the fact that strength did not return to
baseline values during the placebo period that was part
of the extended observations made on the group E5
subjects (Fig. 2).
The changes in MVC seen here are similar in
magnitude and, possibly, time course to changes
Figure 4 Mean change in force, as a percentage of 100 Hz force, at
®ve frequencies of stimulation (1, 10, 20, 50 and 80 Hz). (a) Group E
relative to B1 (n  10), (b) group C relative to week 1 (n  6)
(mean  SEM).
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during the menstrual cycle (Phillips et al. 1996) and
reproductive hormones are known to in¯uence NOS
in skeletal muscle (Weiner et al. 1994). Intuitively, the
possibility of signi®cant growth or other morpho-
logical changes within a few days seems unlikely.
There is, however, evidence that NO is involved in
the control of protein synthesis in a variety of tissues
including skeletal muscle (Fryburg 1996). During
repetitive isometric contraction, NO release from
skeletal muscle increases by ~150% (Balon & Nadler
1994) and it is possible that NO is a link between
high resistance work and gains in strength (including
muscle hypertrophy).
There are no studies pertaining to NO effects on
skeletal muscle properties in vivo, although there are a
number of in vitro studies. The increase in maximum
isometric force with a NO donor that we have found
in vivo is in agreement with only one in vitro study (Reid
et al. 1996). In contrast, there are a number of other
studies that have reported no change or a decrease in
strength (Marechal & Beckers-Bleukx 1996, Morrison
et al. 1996, Galler et al. 1997, Perkins et al. 1997, Chen
et al. 1998, Albertini et al. 1998). It is notable that the
increase in strength we have observed took place over
several days, a longer time scale than any of the in vitro
studies. Reid et al. (1996) found exogenous NO to
increase Ca2+ transients and force and there are a
number of reports that NO donors can affect the Ca2+-
release channels of the sarcoplasmic reticulum
(MeÂszaÂros et al. 1996, Stoyanovsky et al. 1996, 1997,
Aghdasi et al. 1997). It is possible that NO could
augment force by increasing Ca2+ transients. This
increase would be expected to move the entire force±
frequency relationship to the left and Reid et al. (1996)
have reported such a shift corresponding with an
increase in maximum force. In contrast, our observa-
tion of smaller twitches and a general shift of the force±
frequency relationship to the right does not provide a
ready explanation for the increase in maximal force.
The force±frequency relationship was assessed by
the more objective measurement of electrically stimu-
lated forces and is, therefore, unlikely to have been
confounded by subject or observer bias and there was
no consistent or signi®cant change in the control group
over the four weeks of observation. The consistent and
signi®cant (at some frequencies) changes in group E
indicate that GTN administration inhibited the force±
frequency relationship in vivo, causing a slight shift of
the relationship to the right.
The effect of GTN100 on the force±frequency
relationship was more immediate and just as strong as
GTN200, demonstrating an independent time course
and dose response to that of MVC. The change in the
force±frequency relationship was most noticeable in the
sustained drop of twitch force after the ®rst GTN
treatment. In canine skeletal muscle in situ, Murrant
et al. (1997) also found a greater reduction in twitch
than tetanic force following infusion of a NO donor.
Interestingly, L-arginine administration has been found
to be a potent modulator of twitch tension (Ambiel &
Alves-Do-Prado 1997), presumably because it facilitates
endogenous NO production.
The left shift of the force±frequency relationship
with NO donation reported by Reid et al. (1996) is
contrary to other in vitro evidence. Administration of a
NOS inhibitor has been found to cause a left shift of
the force±frequency curve, suggesting that endogenous
NOS activity depresses the force±frequency relation-
ship (Kobzik et al. 1994). In support of this, Perkins
et al. (1997) found exogenous NO to depress the force±
frequency relationship possibly by reducing Ca2+
sensitivity. Andrade et al. (1998) found NO and NO2
±
exposure to increase Ca2+ transients, reduce Ca2+
sensitivity and thus to have no overall effect upon the
force of submaximal tetani. Other investigators have
reported that NO can in¯uence actomyosin ATPase
activity (Galler et al. 1997) and cross-bridge kinetics
(Marechal & Beckers-Bleukx 1996, Morrison et al. 1996,
Galler et al. 1997). Clearly, there is no consensus on the
effects of NO on excitation±contraction coupling.
Andrade et al. (1998) concluded that NO has a multi-
factorial effect on contractile function that is dependant
upon the dose and the precise in vitro preparation.
However, the physiological signi®cance of each of these
effects remains to be elucidated.
In conclusion, NO appears to play a role in skeletal
muscle function in vivo and GTN administration is an
effective means of in¯uencing NO levels in skeletal
muscle. The time course and dose±response relation-
ship of exogenous NO on contractile properties in vivo
requires further elucidation, particularly the surprisingly
slow time course of NO effects upon maximal strength
and how this relates to changes in the force±frequency
relationship. As NO is administered systemically, its
effects should be ubiquitous with the potential to
modulate all manner of muscular actions in sporting
and everyday tasks.
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